AMF Pensionsforsakring AB Increases Stake in Bristol-Myers Squibb Co (BMY)

AMF Pensionsforsakring AB raised its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 89.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 1,883,805 shares of the biopharmaceutical company’s stock after buying an additional 891,213 shares during the period. Bristol-Myers Squibb accounts for 1.3% of AMF Pensionsforsakring AB’s holdings, making the stock its 13th largest position. AMF Pensionsforsakring AB owned approximately 0.11% of Bristol-Myers Squibb worth $110,090,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. West Coast Financial LLC boosted its position in Bristol-Myers Squibb by 0.3% in the third quarter. West Coast Financial LLC now owns 4,806 shares of the biopharmaceutical company’s stock valued at $259,000 after buying an additional 14 shares in the last quarter. Founders Capital Management LLC boosted its position in Bristol-Myers Squibb by 0.4% in the third quarter. Founders Capital Management LLC now owns 4,040 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 18 shares in the last quarter. Shayne & CO. LLC boosted its position in Bristol-Myers Squibb by 0.5% in the third quarter. Shayne & CO. LLC now owns 3,964 shares of the biopharmaceutical company’s stock valued at $214,000 after buying an additional 18 shares in the last quarter. Green Square Capital LLC boosted its position in Bristol-Myers Squibb by 0.3% in the third quarter. Green Square Capital LLC now owns 8,878 shares of the biopharmaceutical company’s stock valued at $479,000 after buying an additional 28 shares in the last quarter. Finally, Oakworth Capital Inc. boosted its position in Bristol-Myers Squibb by 0.4% in the third quarter. Oakworth Capital Inc. now owns 9,625 shares of the biopharmaceutical company’s stock valued at $519,000 after buying an additional 43 shares in the last quarter. 69.67% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Shares of Bristol-Myers Squibb Co (NYSE:BMY) opened at 55.89 on Friday. Bristol-Myers Squibb Co has a one year low of $46.01 and a one year high of $77.12. The company has a market capitalization of $93.49 billion, a PE ratio of 21.09 and a beta of 1.00. The company has a 50-day moving average price of $55.34 and a 200 day moving average price of $54.86.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, January 26th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, missing the consensus estimate of $0.67 by $0.04. Bristol-Myers Squibb had a net margin of 22.94% and a return on equity of 31.39%. The business earned $5.24 billion during the quarter, compared to analysts’ expectations of $5.14 billion. During the same period in the previous year, the business earned $0.38 EPS. The business’s revenue was up 22.3% on a year-over-year basis. Equities analysts anticipate that Bristol-Myers Squibb Co will post $2.82 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, May 1st. Shareholders of record on Friday, April 7th will be issued a $0.39 dividend. The ex-dividend date of this dividend is Wednesday, April 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.79%. Bristol-Myers Squibb’s payout ratio is currently 58.87%.

ILLEGAL ACTIVITY NOTICE: This article was first published by Web Breaking News and is owned by of Web Breaking News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at http://www.webbreakingnews.com/2017/03/25/amf-pensionsforsakring-ab-increases-stake-in-bristol-myers-squibb-co-bmy.html.

Several equities analysts recently weighed in on BMY shares. Jefferies Group LLC decreased their target price on shares of Bristol-Myers Squibb to $60.00 in a research note on Friday, January 27th. Cowen and Company set a $85.00 target price on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Thursday, December 1st. Zacks Investment Research raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $63.00 target price for the company in a research note on Wednesday, December 14th. Vetr cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $62.28 target price for the company. in a research note on Monday, December 12th. Finally, JPMorgan Chase & Co. reissued a “buy” rating on shares of Bristol-Myers Squibb in a research note on Saturday, January 21st. One analyst has rated the stock with a sell rating, twelve have issued a hold rating and ten have assigned a buy rating to the stock. Bristol-Myers Squibb currently has an average rating of “Hold” and an average price target of $61.83.

In related news, insider Louis S. Schmukler sold 5,000 shares of the firm’s stock in a transaction dated Friday, March 17th. The stock was sold at an average price of $56.49, for a total transaction of $282,450.00. Following the transaction, the insider now directly owns 21,483 shares of the company’s stock, valued at approximately $1,213,574.67. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Theodore R. Samuels II acquired 12,000 shares of the firm’s stock in a transaction that occurred on Monday, February 27th. The shares were purchased at an average cost of $56.77 per share, for a total transaction of $681,240.00. Following the completion of the acquisition, the director now owns 12,000 shares in the company, valued at approximately $681,240. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 105,501 shares of company stock worth $6,015,203. Insiders own 0.24% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

5 Day Chart for NYSE:BMY

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Receive News & Ratings for Bristol-Myers Squibb Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Nike Suspends Relationship with Maria Sharapova
Nike Suspends Relationship with Maria Sharapova
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Ron Washington Leaves Texas Rangers Due to an Affair
Ron Washington Leaves Texas Rangers Due to an Affair
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Tony Stewart Case Going to the Grand Jury
Tony Stewart Case Going to the Grand Jury
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder


Leave a Reply

 
© 2006-2017 Web Breaking News.